Cargando…

The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer

INTRODUCTION: Childhood cancer is diagnosed in 400 000 children and young people (CYP) aged 0–19 years worldwide annually. In the UK, a child’s cumulative cancer risk increases from 1 in 4690 from birth to aged 1, to 1 in 470 by age 15. Once diagnosed, access to treatments offers survival to adultho...

Descripción completa

Detalles Bibliográficos
Autores principales: Shanmugavadivel, Dhurgshaarna, Liu, Jo-Fen, Ball-Gamble, Ashley, Polanco, Angela, Vedhara, Kavita, Walker, David, Ojha, Shalini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852751/
https://www.ncbi.nlm.nih.gov/pubmed/35173012
http://dx.doi.org/10.1136/bmjopen-2021-058744
_version_ 1784653102384676864
author Shanmugavadivel, Dhurgshaarna
Liu, Jo-Fen
Ball-Gamble, Ashley
Polanco, Angela
Vedhara, Kavita
Walker, David
Ojha, Shalini
author_facet Shanmugavadivel, Dhurgshaarna
Liu, Jo-Fen
Ball-Gamble, Ashley
Polanco, Angela
Vedhara, Kavita
Walker, David
Ojha, Shalini
author_sort Shanmugavadivel, Dhurgshaarna
collection PubMed
description INTRODUCTION: Childhood cancer is diagnosed in 400 000 children and young people (CYP) aged 0–19 years worldwide annually. In the UK, a child’s cumulative cancer risk increases from 1 in 4690 from birth to aged 1, to 1 in 470 by age 15. Once diagnosed, access to treatments offers survival to adulthood for over 80%. Tumour diagnoses are at a later stage and mortality is higher when compared with those in other parts of Europe. This means higher risk, more intensive therapies for a cure. Some CYPs are known to experience delays to diagnosis which may further contribute to poor outcomes. This study aims to understand the current pathway of childhood cancer referrals and diagnosis and quantify diagnostic intervals in the UK. METHODS AND ANALYSIS: This is a prospective multicentre observational study including all tertiary childhood cancer treatment centres in the UK. CYP (0–18 years) with a new diagnosis of cancer over the study period will be invited to participate. Data will be collected at initial diagnosis and 5 years after diagnosis. Data will include demographic details, clinical symptoms, tumour location, stage and clinical risk group. In addition, key diagnostic dates and referral routes will be collected to calculate the diagnostic intervals. At 5 years’ follow-up, data will be collected on refractory disease, relapse and 1-year and 5-year survival. Population characteristics will be presented with descriptive analyses with further analyses stratified by age, geographical region and cancer type. Associations between diagnostic intervals/delay and risk factors will be explored using multiple regression and logistic regression. ETHICS: The study has favourable opinion from the York and Humber, Leeds West REC (19/YH/0416). DISSEMINATION: Results will be presented at academic conferences, published in peer-reviewed journals and disseminated through public messaging in collaboration with our charity partners through a national awareness campaign (ChildCancerSmart). STUDY REGISTRATION: researchregistry.com (researchregistry5313).
format Online
Article
Text
id pubmed-8852751
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-88527512022-03-03 The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer Shanmugavadivel, Dhurgshaarna Liu, Jo-Fen Ball-Gamble, Ashley Polanco, Angela Vedhara, Kavita Walker, David Ojha, Shalini BMJ Open Paediatrics INTRODUCTION: Childhood cancer is diagnosed in 400 000 children and young people (CYP) aged 0–19 years worldwide annually. In the UK, a child’s cumulative cancer risk increases from 1 in 4690 from birth to aged 1, to 1 in 470 by age 15. Once diagnosed, access to treatments offers survival to adulthood for over 80%. Tumour diagnoses are at a later stage and mortality is higher when compared with those in other parts of Europe. This means higher risk, more intensive therapies for a cure. Some CYPs are known to experience delays to diagnosis which may further contribute to poor outcomes. This study aims to understand the current pathway of childhood cancer referrals and diagnosis and quantify diagnostic intervals in the UK. METHODS AND ANALYSIS: This is a prospective multicentre observational study including all tertiary childhood cancer treatment centres in the UK. CYP (0–18 years) with a new diagnosis of cancer over the study period will be invited to participate. Data will be collected at initial diagnosis and 5 years after diagnosis. Data will include demographic details, clinical symptoms, tumour location, stage and clinical risk group. In addition, key diagnostic dates and referral routes will be collected to calculate the diagnostic intervals. At 5 years’ follow-up, data will be collected on refractory disease, relapse and 1-year and 5-year survival. Population characteristics will be presented with descriptive analyses with further analyses stratified by age, geographical region and cancer type. Associations between diagnostic intervals/delay and risk factors will be explored using multiple regression and logistic regression. ETHICS: The study has favourable opinion from the York and Humber, Leeds West REC (19/YH/0416). DISSEMINATION: Results will be presented at academic conferences, published in peer-reviewed journals and disseminated through public messaging in collaboration with our charity partners through a national awareness campaign (ChildCancerSmart). STUDY REGISTRATION: researchregistry.com (researchregistry5313). BMJ Publishing Group 2022-02-16 /pmc/articles/PMC8852751/ /pubmed/35173012 http://dx.doi.org/10.1136/bmjopen-2021-058744 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
spellingShingle Paediatrics
Shanmugavadivel, Dhurgshaarna
Liu, Jo-Fen
Ball-Gamble, Ashley
Polanco, Angela
Vedhara, Kavita
Walker, David
Ojha, Shalini
The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
title The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
title_full The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
title_fullStr The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
title_full_unstemmed The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
title_short The Childhood Cancer Diagnosis (CCD) Study: a UK observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
title_sort childhood cancer diagnosis (ccd) study: a uk observational study to describe referral pathways and quantify diagnostic intervals in children and young people with cancer
topic Paediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8852751/
https://www.ncbi.nlm.nih.gov/pubmed/35173012
http://dx.doi.org/10.1136/bmjopen-2021-058744
work_keys_str_mv AT shanmugavadiveldhurgshaarna thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT liujofen thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT ballgambleashley thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT polancoangela thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT vedharakavita thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT walkerdavid thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT ojhashalini thechildhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT shanmugavadiveldhurgshaarna childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT liujofen childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT ballgambleashley childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT polancoangela childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT vedharakavita childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT walkerdavid childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer
AT ojhashalini childhoodcancerdiagnosisccdstudyaukobservationalstudytodescribereferralpathwaysandquantifydiagnosticintervalsinchildrenandyoungpeoplewithcancer